
    
      Pembrolizumab is a humanized antibody used in cancer immunotherapy.The NMPA(China) approved
      pembrolizumab for first-line treatment of certain patients with advanced NSCLC.

      This is a multi-center non-interventional study, advanced NSCLC patients who treated with
      pembrolizumab and provide written informed consent will be included. The main objective of
      this study is to evaluate pembrolizumab efficacy and safety in the clinical practice and
      explore the prognosis-relevant factors of advanced NSCLC.
    
  